{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T13:13:42Z","timestamp":1788614022766,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.seminoncol.2026.152539","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T06:33:37Z","timestamp":1786602817000},"page":"152539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Atezolizumab, lurbinectedin, tarlatamab, and FOLFIRNOX in a patient with metastatic small cell carcinoma of the anal canal: A case report and review of the literature"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3585-3287","authenticated-orcid":false,"given":"Ty","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Quick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilder","family":"Widman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Schieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seminoncol.2026.152539_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/341432","article-title":"Extrapulmonary small cell carcinoma of the anal canal: a case report and review of the literature","volume":"2012","author":"Eberhardt","year":"2012","journal-title":"Case Rep Med"},{"key":"10.1016\/j.seminoncol.2026.152539_bib0002","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-023-01464-y","article-title":"Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer","volume":"16","author":"Rudin","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"16","key":"10.1016\/j.seminoncol.2026.152539_bib0003","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.seminoncol.2026.152539_bib0004","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seminoncol.2026.152539_bib0005","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"10495","key":"10.1016\/j.seminoncol.2026.152539_bib0006","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0140-6736(25)01011-6","article-title":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial","volume":"405","author":"Paz-Ares","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.seminoncol.2026.152539_bib0007","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seminoncol.2026.152539_bib0008","article-title":"Small cell carcinoma of anal canal - a rare case report","author":"Surag","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.seminoncol.2026.152539_bib0009","article-title":"A case report of primary neuroendocrine carcinoma of the anal canal with cancer genome profiling","author":"Morita","year":"2024","journal-title":"Intern Med"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152539_bib0010","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.jtho.2021.02.009","article-title":"Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: results from the phase 3 TAHOE study","volume":"16","author":"Blackhall","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.seminoncol.2026.152539_bib0011","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000497336","article-title":"Carboplatin in combination with oral or intravenous etoposide for extra-pulmonary, poorly-differentiated neuroendocrine carcinomas","volume":"109","author":"Frizziero","year":"2019","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.seminoncol.2026.152539_bib0012","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1634\/theoncologist.2019-0361","article-title":"Capecitabine and temozolomide in advanced lung neuroendocrine neoplasms","volume":"25","author":"Al-Toubah","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.seminoncol.2026.152539_bib0013","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2024.7005","article-title":"Efficacy and toxicity analysis of mFOLFIRINOX in high-grade gastroenteropancreatic neuroendocrine neoplasms","volume":"22","author":"Borghesani","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152539_bib0014","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/imj.15907","article-title":"Outcomes of extensive stage extrapulmonary small cell cancer","volume":"53","author":"Gandy","year":"2022","journal-title":"Intern Med J"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152539_bib0015","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/imj.16281","article-title":"A comparison of the outcomes of pulmonary versus extrapulmonary extensive-stage small cell carcinoma","volume":"54","author":"Chen","year":"2023","journal-title":"Intern Med J"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152539_bib0016","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.ejso.2020.04.017","article-title":"Extrapulmonary small cell carcinoma: prognostic factors, patterns of care, and overall survival","volume":"46","author":"Mandish","year":"2020","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152539_bib0017","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae372","article-title":"Efficacy of atezolizumab combined with platinum and etoposide in the treatment of extrapulmonary neuroendocrine carcinoma","volume":"30","author":"Ho","year":"2025","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152539_bib0018","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.3390\/jcm14072264","article-title":"Clinicopathological characteristics of extrapulmonary neuroendocrine carcinomas: treatment responses and survival outcomes: single-center experience","volume":"14","author":"Mu\u011flu","year":"2025","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152539_bib0019","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","article-title":"First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas","volume":"117","author":"Strosberg","year":"2011","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152539_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100364","article-title":"Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms","volume":"7","author":"Al-Toubah","year":"2022","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152539_bib0021","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s12022-022-09722-4","article-title":"Molecular subtypes of extra-pulmonary neuroendocrine carcinomas identified by the expression of neuroendocrine lineage-specific transcription factors","volume":"33","author":"Metovic","year":"2022","journal-title":"Endocr Pathol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775426000849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775426000849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T12:47:48Z","timestamp":1788612468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775426000849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0093775426000849"],"URL":"https:\/\/doi.org\/10.1016\/j.seminoncol.2026.152539","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atezolizumab, lurbinectedin, tarlatamab, and FOLFIRNOX in a patient with metastatic small cell carcinoma of the anal canal: A case report and review of the literature","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seminoncol.2026.152539","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152539"}}